Miami Cardiovascular Innovations Corp.
Minds and Hands Saving LivesTM

Homepage Front Page

HomepageAbout MCVIC

Homepage Services

Homepage Meet the Team


Homepage Careers

Homepage Contact Us

Homepage Mapquest Directions


  Frank Avellanet   favellanet@miacardio.com  Phone: 
1400 NW 10th Avenue,
Ste. 206A
Miami,Florida 33136



June 10,2009

Eduardo de Marchena, M.D., Receives AHA Cor Vitae Award

Published: 06/10/09 11:05 AM EDT

Eduardo de Marchena, M.D., cofounder of Miami Cardiovascular InnovationsCorporation and professor of medicine and surgery and associate dean for international medicine at the University of Miami Miller School of Medicine, was presented with the American Heart Association’s Cor Vitae award at the American Heart Association’s 41st annual Miami-Dade Heart Ball on Saturday, May 30, 2009.

The Cor Vitae award is given to physicians whose focus is in cardiovascular medicine or stroke and who demonstrate outstanding commitment and a proven track record in the Dade County, Florida region. Upon receiving the award, Dr. de Marchena said it was “humbling and a great honor to be recognized by the American Heart Association and to be nominated by such excellent cardiologists, cardiac surgeons and neurologists.”

Together with Frank Avellanet, President and CEO, Dr. de Marchena founded Miami Cardiovascular Innovations Corporation in March of 2006. Dr. de Marchena is an internationally renowned cardiologist who has spearheaded multiple programs in heart transplantation, interventional cardiology and founded the Atherosclerosis Prevention and Treatment Center in addition to leading the International Medicine Institute at the University of Miami Miller School of Medicine. With more than 25 years of clinical experience, Dr. de Marchena is now spearheading cardiovascular treatments overseas.

He is an internationally renowned expert in interventional cardiology, coronary artery disease and congestive heart failure, with studies in more than 200 publications including The New England Journal of Medicine, Circulation and the Journal of the American College of Cardiology. In addition to all his full-time academic and medical duties, Dr. de Marchena provides clinical guidance to Miami Cardiovascular Innovation’s product researchers and engineers.

William O’Neill, M.D., executive dean for clinical affairs at the Miller School presented Dr. de Marchena with the Cor Vitae Award and described him a “leader in every facet of cardiology, from research, to education, and treating patients. Dr. de Marchena is a physician and scientist who continues to set the bar for all of us working to conquer heart disease.”

Miami Cardiovascular Innovations is a privately-held emerging company headquartered in Miami, Florida and engaged in the development of cardiovascular technologies, for more information on the company, please visit www.miacardio.com.

Contacts: Miami Cardiovascular Innovations Corporation
Frank Avellanet, President and CEO, 305-243-4840

July 21,2008

Miami Cardiovascular Innovations featured in Miami Herald

Please click on image above to download PDF copy of Miami Herald article.

July 14,2008

Miami Cardiovascular Innovations featured in ElNuevo Herald

Please click on image above to download PDF copy of elHerald article.

June 21,2008

University of Miami's Miller School of Medicine and Miami Cardiovascular Innovations Partner to Create Biologically Engineered Stents:


Miami Cardiovascular Innovations is pleased to announce an agreement to collaborate in research efforts in the development of biologically engineered medical devices, including coronary stents to overcome late stent thrombosis, pacing leads and other products in the cardiovascular space, with University of Miami's Miller School of Medicine.

The biologically engineered stent -- or BES stent now under development -- for which the company has filed patents and the trademark Progeny, can be implanted via minimally invasive procedure. The agreement will use Miami Cardiovascular's novel stem cell-based stent design and the University of Miami's research laboratories and staff to conduct testing. Miami Cardiovascular's biologically engineered approach to stenting can lead to other procedures that could extend and improve the lives of patients requiring different stents.

"I am delighted to have such a prestigious partner in developing this new, ground-breaking medical device technology," said Frank Avellanet, President & CEO of Miami Cardiovascular. "Our know-how combined with the Miller School of Medicine's expertise will ensure the successful outcome of our collaboration and will allow us to quickly bring this new life-saving device to market."

"This unique opportunity brings The University of Miami and Miami Cardiovascular Innovations together with engineers and scientists to develop clinically useful medical products, including biologically engineered stents. This type of collaboration underscores our commitment to developing new devices and bringing the best new technologies to our patients," said Bart Chernow, M.D., Vice President for Special Programs & Resource Strategy for the University.

About Miami Cardiovascular Innovations

Miami Cardiovascular Innovations is an interdisciplinary company that combines clinical medicine, molecular biology and biomedical engineering. The three sciences are combined to develop biologically engineered devices. Typically devices are products made out of plastic, metal or a combination of both materials. But MCI uses a more sophisticated approach where it adds science to devices -- in this case using stem cells to attract endothelial cells.


Last webpage update (June 19, 2009):


To be a leader in the development of cardiovascular diagnostic and therapeutic devices with a special focus on the next generation of products which merge clinical medicine, vascular biology and biomedical engineering.



© Copyright 2008-9 All Rights Reserved
© Suresh Atapattu